Heart Rhythm
Volume 6, Issue 6 , Pages 752-759, June 2009

Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery

  • Christopher A. Collura, MD

      Affiliations

    • Department of Pediatrics/Division of Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota
  • ,
  • Jonathan N. Johnson, MD

      Affiliations

    • Department of Pediatrics/Division of Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota
  • ,
  • Christopher Moir, MD

      Affiliations

    • Department of Surgery/Division of Pediatric Surgery, Mayo Clinic, Rochester, Minnesota
  • ,
  • Michael J. Ackerman, MD, PhD

      Affiliations

    • Department of Pediatrics/Division of Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota
    • Department of Medicine/Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
    • Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota
    • Corresponding Author InformationAddress reprint requests and correspondence: Dr. Michael J. Ackerman, Long QT Syndrome Clinic and the Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Guggenheim 501, 200 First Street SW, Rochester, Minnesota 55905

published online 20 March 2009.

Background

Long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT) are two of the most common, potentially lethal, cardiac channelopathies. Treatment strategies for the primary and secondary prevention of life-threatening polymorphic ventricular tachycardia/fibrillation include pharmacotherapy with β-blockers, implantable cardioverter defibrillators, and left cardiac sympathetic denervation (LCSD).

Objectives

This study sought to report our institutional experience with LCSD using video-assisted thoracic surgery (VATS).

Methods

From November 2005 through November 2008, 20 patients (8 female, average age at surgery 9.1 ± 9.7 years, range 2 months to 42 years) underwent LCSD via either a traditional approach (N = 2) or VATS (N = 18). A total of 12 patients had genotype-positive LQTS (7 LQT1, 2 LQT2, 1 LQT3, 2 LQT1/LQT2), 2 had JLNS, 4 had genotype-negative LQTS, and 2 had CPVT1. Electronic medical records were reviewed for patient selection, perioperative complications, and short-term outcomes.

Results

LCSD was performed as a secondary prevention strategy in 11 patients (8 LQTS patients, average QTc 549 ms) and as primary prevention in 9 patients (average QTc 480 ms). There were no perioperative complications, including no intraoperative ectopy, no uncontrolled hemorrhage, and no VATS cases requiring conversion to a traditional approach. The average length of available follow-up was 16.6 ± 9.5 months (range 4 to 40 months). Among the 18 patients who underwent VATS-LCSD, the average time from operation to dismissal was 2.6 days (range 1 day to 15 days), the majority being next-day dismissals. Among those receiving LCSD as secondary prevention, there has been a marked reduction in cardiac events.

Conclusions

We present a series of 20 patients with LQTS and CPVT who underwent LCSD, 18 using VATS. The minimally invasive VATS surgical approach was associated with minimal perioperative complications, including no intraoperative ectopy and excellent immediate and short-term outcomes. Videoscopic denervation surgery, in addition to traditional LCSD, offers a safe and effective treatment option for the personalized medicine required for patients with LQTS/CPVT.

Keywords: Left cardiac sympathetic denervation, long QT syndrome, CPVT, VATS, denervation, LQTS

 

 Dr. Ackerman's research program was supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program, the Dr. Scholl Foundation, the CJ Foundation for SIDS, Hannah Wernke Memorial Foundation, an Established Investigator Award from the American Heart Association, and the National Institutes of Health (HD42569).

 Dr. Ackerman is a consultant for PGxHealth, Medtronic, and Pfizer.

PII: S1547-5271(09)00315-4

doi:10.1016/j.hrthm.2009.03.024

Heart Rhythm
Volume 6, Issue 6 , Pages 752-759, June 2009